🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

39 results for “Indivior Europe Limited” Clear

  1. 2.0mg Buprenorphine/0.5mg Naloxone

    Indivior Europe Limited

    Hepatic Failure

    approved small molecule completed

    1 trial

  2. Buprenorphine (Subutex)

    Indivior Europe Limited

    Opioid Dependency

    approved small molecule completed

    1 trial

  3. Buprenorphine + naloxone (Suboxone)

    Indivior Europe Limited

    Opiate Dependence

    approved small molecule completed

    1 trial

  4. Buprenorphine Extended-Release Injection

    Indivior Europe Limited

    Opioid Use Disorder

    approved small molecule completed

    1 trial

  5. PERSERIS

    Indivior Europe Limited

    Schizophrenia

    approved small molecule completed

    1 trial

  6. Sublocade

    Indivior Europe Limited

    Opioid Use Disorder, Severe

    approved small molecule completed

    1 trial

  7. Suboxone Sublingual Film

    Indivior Europe Limited

    Opioid Dependence

    approved small molecule completed

    1 trial

  8. Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484

    Indivior Europe Limited

    Opiate Dependence

    approved small molecule completed

    1 trial

  9. Subutex 300 mg injektionsvätska, depotlösning, Subutex 100 mg injektionsvätska, depotlösning

    Indivior Europe Limited

    Opioid Use Disorder

    approved small molecule active

    1 trial

  10. TM buprenorphine

    Indivior Europe Limited

    Opioid-use Disorder

    approved small molecule completed

    1 trial

  11. Transmucosal Buprenorphine

    Indivior Europe Limited

    Moderate to Severe Opioid-use Disorder

    approved small molecule completed

    1 trial

  12. buprenorphine

    Indivior Europe Limited

    Opiate-related Disorders

    approved small molecule completed

    1 trial

  13. buprenorphine

    Indivior Europe Limited

    Hepatitis C, Chronic

    approved small molecule terminated

    1 trial

  14. buprenorphine and low-dose naloxone

    Indivior Europe Limited

    Pain

    small molecule completed

    1 trial

  15. morphine sulfate

    Indivior Europe Limited

    Analgesic Response

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources